Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00871481 · ClinicalTrials.gov registry record · Phase 1
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00871481 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT00871481, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects of giving laboratory-treated T cells and ipilimumab together to see how well they work in treating patients with metastatic melanoma. Treating a patient's T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving laboratory-treated T cells together with ipilimumab may kill more tumor cells
Interventions
- DRUG cyclophosphamide
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- BIOLOGICAL aldesleukin
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00871481
The ClinicalTrials.gov registry entry for NCT00871481 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00871481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00871481 about?
NCT00871481 is a clinical study titled "Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma". This phase I/II trial is studying the side effects of giving laboratory-treated T cells and ipilimumab together to see how well they work in treating patients with metastatic melanoma. Treating a patient's T cells in the laboratory may help the T cells kill more tumor cells when they are put back in...
What is the current status of trial NCT00871481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-02. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00871481?
The interventions under investigation include: cyclophosphamide (DRUG), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), aldesleukin (BIOLOGICAL), ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00871481?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.